锐客网

  1. 首页 > 生活杂烩 > 健康 > >

ibd|IBD伴肠外表现，如何选择生物制剂( 三 )


12. Ann Gastroenterol. 2011; 24(3): 173–180.
13. Allen PB, et al. Therap Adv Gastroenterol. 2017 Nov;10(11)865-8706.
14. Felice C, et al. Expert Rev Clin Immunol. 2018 Sep;14(9)751-759.
15. Lee HJ, et al. Intest Res. 2017 Jul;15(3)380-387.
16. Eppinga H, et al. Inflamm Bowel Dis. 2017 Oct;23(10)1783-1789
17. Agarwal A, et al. Aliment Pharmacol Ther. 2013 Sep;38(6):563-72.
18. Vavricka SR, et al. Inflamm Bowel Dis. 2017;23(7):1174-1181.
19. 贾燕等. 胃肠病学和肝病学杂志. 2018; 27(5): 513-517
20. Lupascu et al. / Digestive and Liver Disease 36 (2004) 423–425
21. C Liefferinckx, et al. Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, 1 2018. S031–S032
22. PuglieseD et al. Dig Liver Dis 2019 07;51(7) 972-977
23. Figueiredo ML et al. J Crohns Colitis 2019 Oct 20
24. Harbord M, et al. J Crohns Colitis. 2016. PMID: 26614685
25. 中华医学会消化病学分会炎症性肠病学组.抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J].协和医学杂志,2017,8(4):239-243.
26. Biemans et al. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. JCC 2020.
27. Fahmy et al. Ustekinumab for peristomal pyoderma gangrenosum. AmJG 2012.
28. Goldminz et al. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol 2012.
29. Guenova et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011.
30. Greb et al. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther 2016.
31. Nunes et al. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab. JCC 2019.
32. De Risi-Pugliese et al. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study. J Am Acad Dermatol 2019.
33. Benzaquen et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab. Australas J Dermatol 2017.
34. Vallerand et al. Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report. SAGE 2019.
35. Low et al. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. Australas J Dermatol 2018.
36. Gheita et al. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin rheumatol 2014.
37. Matsumoto et al. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease. Biologics 2018.
38. Deodhar et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol 2019.
39. Pugliese et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. DLD 2019.
40. Ryan et al. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010.
41. Chateau T et al. Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn’s Disease. JCC 2020.
42. Liefferinckx et al. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study. JCC 2019.
43. Bertrand V et al. Efficiency of Ustekinumab in Crohn’s Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent. Pediatr Dermatol 2017.
44. Nunes G et al. Refractory Pyoderma Gangrenosum in a Patient With Crohn’s Disease: Complete Response to Ustekinumab. JCC 2019.
【ibd|IBD伴肠外表现，如何选择生物制剂】45. Barrie A, Regueiro M. Inflamm Bowel Dis 2007;13:1424–9.

推荐阅读


上一篇：尿毒症|患上糖尿病，出现这4种表现，可能得当心尿毒症“缠身”

下一篇：头晕|一站起来就头晕，我这是怎么了？